1921
Volume 99, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Limited access to nucleic acid tests for hepatitis B virus (HBV) DNA is a significant barrier to the effective management of chronic HBV infection in resource-poor countries. Alternatively, HBV e antigen (HBeAg) may accurately indicate high viral replication. We assessed the diagnostic performance of three commercially available rapid diagnostic tests (RDTs) for HBeAg (SD Bioline, Insight and OneStep) against a quantitative chemiluminescent immunoassay (CLIA, Architect). Using stored sera from adults with chronic HBV infection, we tested RDTs in three groups in Senegal (48 HBeAg-positive, 196 HBeAg-negative, and 117 cases with high HBV DNA (≥ 10 IU/mL)) and one group in France (17 HBeAg-positive East Asians). In Senegal, the sensitivity and specificity for HBeAg detection were 29.8% and 100% for SD Bioline, 31.1% and 100% for Insight, and 42.5% and 98.4% for OneStep, respectively. The lower limits of detection of these RDTs were very high (> 2.5 log10 Paul Ehrlich Institut units/mL). Their low sensitivity was also confirmed in HBeAg-positive Asian samples (35.3–52.9%). The prevalence of HBeAg in highly viremic (≥ 10 IU/mL) Senegalese patients was low: 58.1% using CLIA and 24.5–37.5% using RDTs. Hepatitis B e antigen prevalence was similarly low in a subgroup of 28 Senegalese women of childbearing age with a high viral load (≥ 10 IU/mL). Approximately, half of highly viremic adults do not carry HBeAg in Africa, and HBeAg RDTs had remarkably poor analytical and diagnostic sensitivity. This implies that HBeAg-based antenatal screening, particularly if using the currently available HBeAg RDTs, may overlook most pregnant women at high risk of mother-to-child transmission in Africa.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.18-0116
2018-06-04
2019-09-22
Loading full text...

Full text loading...

/deliver/fulltext/14761645/99/2/tpmd180116.html?itemId=/content/journals/10.4269/ajtmh.18-0116&mimeType=html&fmt=ahah

References

  1. Stanaway JD, 2016. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet 388: 10811088. [Google Scholar]
  2. WHO, 2016. Global Health Sector Strategy on Viral Hepatitis 2016–2021. Geneva, Switzerland: World Health Organization, 1–56.
  3. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ, , 2015. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 6736: 110. [Google Scholar]
  4. Nayagam S, Thursz M, Sicuri E, Conteh L, Wiktor S, Low-Beer D, Hallett TB, , 2016. Requirements for global elimination of hepatitis B: a modelling study. Lancet Infect Dis 16: 13991408. [Google Scholar]
  5. Shimakawa Y, 2016. Natural history of chronic HBV infection in West Africa: a longitudinal population-based study from the Gambia. Gut 65: 20072016. [Google Scholar]
  6. World Health Organization, 2009. Hepatitis B vaccines. Wkly Epidemiol Rec 84: 405419. [Google Scholar]
  7. Keane E, Funk AL, Shimakawa Y, , 2016. Systematic review with meta-analysis: the risk of mother-to-child transmission of hepatitis B virus infection in sub-Saharan Africa. Aliment Pharmacol Ther 44: 10051017. [Google Scholar]
  8. Wen WH, Chang MH, Zhao LL, Ni YH, Hsu HY, Wu JF, Chen PJ, Chen DS, Chen HL, , 2013. Mother-to-infant transmission of hepatitis B virus infection: significance of maternal viral load and strategies for intervention. J Hepatol 59: 2430. [Google Scholar]
  9. Visvanathan K, 2016. Managing HBV in pregnancy. Prevention, prophylaxis, treatment and follow-up: position paper produced by Australian, UK and New Zealand key opinion leaders. Gut 65: 340350. [Google Scholar]
  10. Lemoine M, Thursz MR, , 2017. Battlefield against hepatitis B infection and HCC in Africa. J Hepatol 66: 645654. [Google Scholar]
  11. WHO, 2017. Global Hepatitis Report, 2017. Geneva, Switzerland: World Health Organization, 1–68.
  12. WHO, 2018. World Health Organization Model List of Essential In Vitro Diagnostics, 1st edition. Geneva, Switzerland: World Health Organization, 1–35.
  13. Kramvis A, , 2016. The clinical implications of hepatitis B virus genotypes and HBeAg in pediatrics. Rev Med Virol 26: 285303. [Google Scholar]
  14. Bossuyt PM, 2015. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. Radiology 277: 826832. [Google Scholar]
  15. Clement F, Dewint P, Leroux-Roels G, , 2002. Evaluation of a new rapid test for the combined detection of hepatitis B virus surface antigen and hepatitis B virus e antigen. J Clin Microbiol 40: 46034606. [Google Scholar]
  16. Lau DT-Y, Ma H, Lemon SM, Doo E, Ghany MG, Miskovsky E, Woods GL, Park Y, Hoofnagle JH, , 2003. A rapid immunochromatographic assay for hepatitis B virus screening. J Viral Hepat 10: 331334. [Google Scholar]
  17. Akanmu AS, Esan OA, Adewuyi JO, Davies AO, Okany CC, Olatunji RO, Babalola T, , 2006. Evaluation of a rapid test kit for detection of HBsAg/eAg in whole blood: a possible method for pre-donation testing. Afr J Med Med Sci 35: 58. [Google Scholar]
  18. Mainet-González D, Palenzuela-Gardon DO, Aguilar Rubido JC, , 2009. Comparison between an immunochromatographic test with an amplified ELISA for detecting e antigen and anti-e antigen antibodies in chronic hepatitis B. Biotecnol Apl 26: 143145. [Google Scholar]
  19. Vray M, Debonne J, Sire J-M, Tran N, Chevalier B, Plantier J-C, Fall F, Vernet G, Mb PS, Simon F, , 2006. Molecular epidemiology of hepatitis B virus in Dakar, Sénégal. J Med Virol 78: 329334. [Google Scholar]
  20. Burk RD, Hwang L-Y, Ho GYF, Shafritz DA, Beasley RP, , 1994. Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load. J Infect Dis 170: 14181423. [Google Scholar]
  21. Pan CQ, Duan Z, Bhamidimarri KR, Zou H, Liang X, Li J, Tong MJ, , 2012. An algorithm for risk assessment and intervention of mother to child transmission of hepatitis B virus. Clin Gastroenterol Hepatol 10: 452459. [Google Scholar]
  22. Terrault NA, Bzowej NH, Chang K-M, Hwang JP, Jonas MM, Murad MH, , 2016. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 63: 261283. [Google Scholar]
  23. European Association for the Study of the Liver, 2017. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol 67: 370398. [Google Scholar]
  24. Andriamandimby SF, Olive M, Shimakawa Y, Rakotomanana F, Razanajatovo IM, Andrianinarivomanana TM, Ravalohery J, Andriamamonjy S, Rogier C, Heraud J-M, , 2017. Prevalence of chronic hepatitis B virus infection and infrastructure for its diagnosis in Madagascar: implication for the WHO’s elimination strategy. BMC Public Health 17: 636. [Google Scholar]
  25. Kubo A, Shlager L, Marks AR, Lakritz D, Beaumont C, Gabellini K, Corley DA, , 2014. Prevention of vertical transmission of hepatitis B. Ann Intern Med 160: 828. [Google Scholar]
  26. Thompson AJV, 2010. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 51: 19331944. [Google Scholar]
  27. Fujiko M, 2015. Chronic hepatitis B in pregnant women: is hepatitis B surface antigen quantification useful for viral load prediction? Int J Infect Dis 41: 8389. [Google Scholar]
  28. Ducancelle A, Abgueguen P, Birguel J, Mansour W, Pivert A, Le Guillou-Guillemette H, Sobnangou JJ, Rameau A, Huraux JM, Lunel-Fabiani F, , 2013. High endemicity and low molecular diversity of hepatitis B virus infections in pregnant women in a rural district of north Cameroon. PLoS One 8: 1012. [Google Scholar]
  29. Shimakawa Y, Toure-Kane C, Mendy M, Thursz M, Lemoine M, , 2016. Mother-to-child transmission of hepatitis B in sub-Saharan Africa. Lancet Infect Dis 16: 1920. [Google Scholar]
  30. Dumpis U, Mendy M, Hill A, Thursz M, Hall A, Whittle H, Karayiannis P, , 2001. Prevalence of HBV core promoter/precore/core mutations in Gambian chronic carriers. J Med Virol 65: 664670. [Google Scholar]
  31. Wursthorn K, Zacher BJ, Jaroszewicz J, Darnedde M, Manns M, Wedemeyer H, , 2011. Development of a protocol for the quantitative determination of HBeAg using the Elecsys® HBeAg immunoassay. J Viral Hepat 18: 179183. [Google Scholar]
  32. Maylin S, 2013. Quantification of hepatitis B e antigen between Elecsys HBeAg and Architect HBeAg assays among patients infected with hepatitis B virus. J Clin Virol 56: 306311. [Google Scholar]
  33. Maylin S, 2012. Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV–hepatitis B virus-infected patients. AIDS 26: 939949. [Google Scholar]
  34. Mendy ME, McConkey SJ, van der Sande MAB, Crozier S, Kaye S, Jeffries D, Hall AJ, Whittle HC, , 2008. Changes in viral load and HBsAg and HBeAg status with age in HBV chronic carriers in the Gambia. Virol J 5: 49. [Google Scholar]
  35. Lemoine M, 2016. Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in the Gambia: the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) study. Lancet Glob Health 4: e559e567. [Google Scholar]
  36. Shimakawa Y, Seck A, Nayagam S, Toure-Kane C, Lemoine M, , 2018. Screening strategies to prevent mother-to-child transmission of hepatitis B in sub-Saharan Africa. Lancet Gastroenterol Hepatol 3: 222223. [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.18-0116
Loading
/content/journals/10.4269/ajtmh.18-0116
Loading

Data & Media loading...

Supplemental Figures and Tables

  • Received : 08 Feb 2018
  • Accepted : 23 Apr 2018
  • Published online : 04 Jun 2018

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error